← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	BLCM 26 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	96	+16	+20%	$263M
27	27 Lineage Cell Therapeutics LCTX $242M	96	+4	+4%	$161M
28	AGTC 28 DELISTED Applied Genetic Technologies Corporation AGTC	89	-1	-1%	$75.8M
29	NSTG 29 DELISTED NanoString Technologies, Inc. NSTG	89	-22	-20%	$389M
30	30 Atara Biotherapeutics ATRA $92.6M	85	-1	-1%	$493M
31	31 Regenxbio RGNX $460M	85	+7	+9%	$401M
32	32 Veracyte VCYT $3.66B	84	+10	+14%	$198M
33	33 Arrowhead Research ARWR $8.26B	83	-2	-2%	$45M
34	34 Standard BioTools LAB $260M	80	-3	-4%	$154M
35	ATHX 35 DELISTED Athersys, Inc. Common Stock ATHX	76	-3	-4%	$33.7M
36	36 Intellia Therapeutics NTLA $1.63B	76	+6	+9%	$236M
37	37 DELISTED Adverum Biotechnologies ADVM	75	-8	-10%	$36.5M
38	38 Invesco Biotechnology & Genome ETF PBE $431M	68	0	0%	$55M
39	39 Rocket Pharmaceuticals RCKT $250M	67	-15	-18%	$20.7M
40	NVTA 40 DELISTED Invitae Corporation NVTA	65	+1	+2%	$300M
41	41 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	64	+12	+23%	$868M
42	42 Abeona Therapeutics ABEO $269M	58	+4	+7%	$71.6M
43	43 Arbutus Biopharma ABUS $842M	53	-2	-4%	$118M
44	44 Fate Therapeutics FATE $231M	53	+16	+43%	$114M
45	ADAP 45 DELISTED Adaptimmune Therapeutics ADAP	49	+9	+23%	$219M
46	46 Wave Life Sciences WVE $615M	49	-2	-4%	$432M
47	47 Fortress Biotech FBIO $64.7M	48	-3	-6%	$24M
48	48 Voyager Therapeutics VYGR $126M	47	-9	-16%	$146M
49	49 Cartesian Therapeutics RNAC $199M	46	+3	+7%	$124M
50	50 Vericel Corp VCEL $2.11B	42	-4	-9%	$29.3M